Published in Pharma Investments, Ventures and Law Weekly, December 26th, 2004
"We examined the cellular and molecular consequences of cisplatin treatment using two ovarian tumor xenograft models that had not been previously adapted to culture in vitro. Both xenografts were curable with clinically relevant multiple doses of cisplatin," reported Cancer Research UK scientist P.A. Clarke and colleagues.
"Following a single dose of cisplatin (6 mg/kg i.p.) growth delays of 25 and 75 days were obtained for pxn100 and pxn65, respectively," they said, noting that the...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Investments, Ventures and Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.